Who is sponsoring NCT00948493?

NCT00948493 is sponsored by Generex Biotechnology Corp..

What condition does NCT00948493 study?

NCT00948493 studies Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus.

What drugs are being tested in NCT00948493?

Interventions: Buccal insulin spray.

What is the status of NCT00948493?

NCT00948493 is currently NO_LONGER_AVAILABLE.

Last reviewed 2013-03-18 · How we verify

An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn™ in Patients With Type 1 or Type 2 Diabetes Mellitus

NCT00948493 NO_LONGER_AVAILABLE

The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of diabetes, and who are not eligible to participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). This protocol is intended as a substitute for the Single Patient IND mechanism to obtain Generex Oral-lyn™.

Details

Lead sponsor	Generex Biotechnology Corp.
Status	NO_LONGER_AVAILABLE

Conditions

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions

Buccal insulin spray